Bolt Biotherapeutics Inc

-0.05 (-4.59%)
5:24:31 PM EDT: $1.06 +0.02 (+1.92%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)37.66M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.78 Million
Adjusted EPS-$0.53
See more estimates
10-Day MA$1.10
50-Day MA$1.21
200-Day MA$1.42
See more pivots

Bolt Biotherapeutics Inc Stock, NASDAQ:BOLT

900 Chesapeake Drive, Redwood City, California 94063
United States of America
Phone: +1.650.665.9295
Number of Employees: 94


Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.